-
2025-523486-17-00
5
2026-06-16
Obesity
-
2025-523704-77-00
4
2026-06-04
Geographic atrophy secondary to age-related macular degeneration
-
2025-522091-84-00
4
2026-05-29
Merkel Cell Carcinoma
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-523229-16-00
4
2026-04-27
locally advanced basal cell carcinoma patients
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-523079-44-00
5
2026-04-15
Turner Syndrome (TS)
-
2025-522583-32-00
5
2026-04-13
Cold-Induced Urticaria and Symptomatic Dermographism
-
2025-522387-32-00
5
2026-04-10
Uveal Melanoma
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2024-518236-36-00
5
2026-03-12
Locoregionally restricted (stage III) small intestinal neuroendocrine
-
2024-518273-34-02
3
2026-03-02
Malaria
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521372-62-00
4
2026-01-29
Acute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acute Myeloid Le
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2024-519748-34-00
4
2026-01-23
Infections with multidrug-resistant Enterobacteriaceae
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)